-
Views
-
Cite
Cite
Simona Pollini, Alberto Antonelli, Claudia Venturelli, Simona Maradei, Alberto Veggetti, Silvia Bracco, Fabio Rumpianesi, Francesco Luzzaro, Gian Maria Rossolini, Acquisition of plasmid-borne blaIMP-19 gene by a VIM-1-positive Pseudomonas aeruginosa of the sequence type 235 epidemic lineage, Journal of Antimicrobial Chemotherapy, Volume 68, Issue 3, March 2013, Pages 722–724, https://doi.org/10.1093/jac/dks440
- Share Icon Share
Extract
Sir,
Acquired metallo-β-lactamases (MBLs) are the most common acquired carbapenemases in Pseudomonas aeruginosa. They confer a broad-spectrum β-lactam resistance profile, including resistance to the antipseudomonal penicillins, cephalosporins and carbapenems, that is not antagonized by the available β-lactamase inhibitors. Most MBL-producing strains exhibit a multidrug resistance profile, also including resistance to non-β-lactams, due to the accumulation of additional resistance determinants.1
Although several types of acquired MBLs have been detected in P. aeruginosa, the IMP- and VIM-type enzymes are currently the most widespread.1 A number of genes encoding these enzymes (e.g. blaVIM-1, blaVIM-2, blaVIM-4 and blaIMP-1) have become associated with high-risk clones, such as clonal complex (CC) 235 and CC111, which has promoted their dissemination in Europe and other continents.2
IMP-19 is an IMP allelic variant that was originally detected in Enterobacter cloacae (GenBank/EMBL accession no. AB201264) and P. aeruginosa (GenBank/EMBL accession no. AB184976) from Japan and, subsequently, in an Aeromonas caviae isolated in France.3 More recently, it has been reported in Achromobacter xylosoxidans and Acinetobacter spp. isolates from Japan.4,5